Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologs while sparing paralogous pr
(Phys.org) -- New drug candidates require testing in animal models prior to approval for clinical use. A recently developed antagonist based on a bicyclic peptide inhibited the human serine protease plasma kallikrein potently ...
